


**Supplemental Figure A.** Flow chart of participants' selection

REM: rapid eye movement sleep; iRBD: isolated REM sleep behavior disorder; PD: Parkinson's disease; MSA: multisystem atrophy; TST: total sleep time; AHI: apnea-hypopnea index



**Supplemental Table A. Demographic characteristics and polysomnographic measures of patients with multiple system atrophy (MSA), Parkinson's disease (PD), isolated REM sleep behavior disorder (iRBD) and controls**

	<b>MSA A</b>	<b>PD B</b>	<b>iRBD C</b>	<b>Controls D</b>	<b>P value</b>	<b>Post-hoc test</b>
<b>Number</b>	73	257	111	115	—	—
<b>Sex, female N (%)</b>	42 (57.5)	78 (30.4)	23 (20.7)	68 (59.1)	<.001	A = D > B = C
<b>Age, y</b>	63.0 (9.0)	65.4 (10.2)	67.2 (9.0)	62.6 (7.7)	<.001	A < C, B = C > D
<b>Benzodiazepine N (%)</b>	6 (8.22)	21 (8.2)	13 (11.61)	10 (8.7)	0.754	
<b>Antidepressants N (%)</b>	34 (46.58)	59 (23.05)	13 (11.61)	16 (13.91)	<.001	A > B > C = D
<b>Total sleep time, min</b>	385.4 (75.0)	389 (79.2)	432.9 (84.8)	402.3 (71)	<.001	A = B < C, C > D
<b>Sleep efficiency, %</b>	77.1 (10.4)	79.2 (11.8)	80.9 (9.4)	81.5 (11)	0.022	A < D
<b>Latency to, min</b>						
<b>Sleep</b>	28.6 (27.3)	19.3 (23.8)	25.1 (20.5)	21.9 (19.8)	0.009	A > B
<b>REM sleep</b>	168.7 (116.2)	147.5 (91.8)	115.9 (79)	105.2 (63.3)	<.001	A = B > C = D
<b>Sleep stages, % of total sleep time</b>						
<b>N1</b>	4.7 (3.8)	4.9 (4.9)	5.4 (4.4)	3.7 (3)	0.024	C > D
<b>N2</b>	52.4 (14)	52.8 (13.3)	51.8 (9.8)	52.3 (9.2)	0.894	
<b>N3</b>	25.9 (9.6)	25.2 (12.3)	23.4 (9.5)	21.3 (11.6)	0.01	A = B > D
<b>REM</b>	17.4 (9.2)	17.2 (8.2)	19.8 (7)	19.2 (5.4)	0.005	B < C
<b>Apnea-hypopnea index, /h</b>	14.0 (17.3)	8.8 (11.2)	10 (13.7)	4.8 (4.2)	<.001	A > B, A > D, B = C > D
<b>Obstructive</b>	9.7 (17.4)	13.2 (31)	14.3 (28.5)	4.2 (8.6)	0.009	B = C > D
<b>Mixed</b>	1.7 (6.7)	1.4 (9.6)	0.7 (4.1)	0 (0)	0.291	
<b>Central</b>	9.6 (20.7)	4.8 (21.4)	2.8 (6.7)	0.7 (1.1)	0.003	A > C = D
<b>Minimal oxygen saturation, %</b>	85.7 (5.9)	85.9 (8.2)	86.6 (6.5)	87.9 (4.5)	0.009	NA
<b>Periodic leg movement index, /h</b>	45.4 (56.7)	13.5 (26.5)	18.7 (24.3)	8.8 (17)	<.001	A > B = C = D
<b>Arousal index, /h</b>	10.1 (7.9)	9.2 (7.4)	13.1 (9.8)	9 (5.9)	0.001	B = D < C

Data are mean (SD) or N (%)

**Supplemental Table B. The Bayes Factor of the model (BF<sub>M</sub>) or the probability of the model knowing the data (p(M|data)) indicates that the model including the groups far outweighs the null model of which one is a certainty.**

<b>Models comparison</b>	<b>P(M)</b>	<b>P(M data)</b>	<b>BF<sub>M</sub></b>	<b>BF<sub>10</sub></b>	<b>Error %</b>
<b>Group</b>	0.500	1.000	$3.237 \times 10^{+8}$	1.000	
<b>Null model</b>	0.500	$3.089 \times 10^{-9}$	$3.089 \times 10^{-9}$	$3.089 \times 10^{-9}$	$1.318 \times 10^{-4}$

**Supplemental Table C. The group with MSA are different from the other groups with extreme evidence (BF>100). There are no differences between the subjects suffering from PD compared to the group of subjects iRBD and VS (BF<3) as well as the subjects iRBD compared to the control.**

**Post Hoc Tests Comparisons - Groups**

<b>Group 1</b>	<b>Group 2</b>	<b>Prior Odds</b>	<b>Posterior Odds</b>	<b>BF<sub>10</sub></b>	<b>Error %</b>
<b>MSA</b>	<b>PD</b>	1.000	$1.813 \times 10^{+6}$	$1.813 \times 10^{+6}$	$8.276 \times 10^{-13}$
	<b>iRBD</b>	1.000	111792.289	111792.289	$7.473 \times 10^{-12}$
	<b>Control</b>	1.000	797.114	797.114	$2.518 \times 10^{-9}$
<b>PD</b>	<b>iRBD</b>	1.000	0.205	0.205	0.073
	<b>Control</b>	1.000	0.198	0.198	0.076
<b>iRBD</b>	<b>Control</b>	1.000	1.044	1.044	0.017

**Supplemental Table D. Autonomic measures ( orthostatic hypotension, number of stools/week,) smell performances**

<b>RBD patients</b>	<b>Threshold &gt; 3.4</b>	<b>Threshold &lt; 3.4</b>	<b>P-Value</b>
	n = 11	n = 100	
<b>Orthostatic hypotension</b>			
N	6/11	75/100	
N (%)	1 (9.1)	7 (6.9)	0.473
<b>Constipation</b>			
N	6/11	75 / 100	
N (%)	2 (18.2)	27 (26.7)	0.569
Number of stools/week	4.5 (2.3)	3.1 (2.4)	0.166
<b>Smell performances</b>			
N	4/11	61 / 100	
Normal > 8 / 12	1 (25)	20 (32.7)	0.6374

## **Legend of the Supplementary video-clips**

### **Supplementary video clip 1**

Video, sound and cardiorespiratory monitoring during N3 sleep in an MSA participant with sighs in ambient air (epoch of 5 min). The visible sigh is silent; however, chest movement and shoulders lifting are visible during the sigh. This is the most common case.

### **Supplementary video clip 2**

Video, sound and cardiorespiratory monitoring during N3 sleep in an MSA participant with stridor (epoch of 5 min) in ambient air. When a sigh occurs during a stridorous respiration, a sharp noise can be heard during the sigh, which first manifests as an increase in stridor during the inspiratory phase of the sigh and later as a short moaning during the expiratory phase. During the central apnea following the sigh, there is no sound or catathrenia.